Novavax Stock Price, News & Analysis (NASDAQ:NVAX)

$1.29 0.06 (4.88 %)
(As of 11/18/2017 03:48 AM ET)
Previous Close$1.29
Today's Range$1.39 - $1.22
52-Week Range$0.73 - $1.78
Volume10.71 million shs
Average Volume5.95 million shs
Market Capitalization$361.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:NVAX
  • CUSIP: 67000210
  • Web: www.novavax.com
Debt:
  • Debt-to-Equity Ratio: -4.28%
  • Current Ratio: 3.31%
  • Quick Ratio: 3.31%
Sales & Book Value:
  • Annual Sales: $15.35 million
  • Price / Sales: 26.36
  • Book Value: ($0.24) per share
  • Price / Book: -5.38
Profitability:
  • Trailing EPS: ($0.68)
  • Net Income: ($279,960,000.00)
  • Net Margins: -726.35%
  • Return on Equity: -787.38%
  • Return on Assets: -52.58%
Misc:
  • Employees: 355
  • Outstanding Shares: 313,620,000
 

Frequently Asked Questions for Novavax (NASDAQ:NVAX)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.35 million during the quarter, compared to analysts' expectations of $6.42 million. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The firm's revenue was up 158.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.24) EPS. View Novavax's Earnings History.

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

7 brokerages have issued 12 month target prices for Novavax's stock. Their predictions range from $1.50 to $12.00. On average, they expect Novavax's stock price to reach $3.43 in the next year. View Analyst Ratings for Novavax.

What are Wall Street analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (11/16/2017)
  • 2. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
  • 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Are investors shorting Novavax?

Novavax saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 40,037,310 shares, a decrease of 10.2% from the October 13th total of 44,569,528 shares. Based on an average daily volume of 3,915,223 shares, the days-to-cover ratio is currently 10.2 days. Currently, 13.8% of the shares of the company are short sold.

Who are some of Novavax's key competitors?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:

  • James Francis Young Ph.D., Independent Chairman of the Board (Age 64)
  • Stanley C. Erck, President, Chief Executive Officer, Interim Chief Financial Officer, Director (Age 68)
  • Gregory M. Glenn M.D., President, Research and Development (Age 63)
  • John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary (Age 52)
  • John J. Trizzino, Senior Vice President - Commercial Operations (Age 57)
  • James F. Cummings, Vice President - Clinical Development and Translational Medicine
  • Rajiv I. Modi Ph.D., Director (Age 56)
  • Richard H. Douglas Ph.D., Independent Director (Age 64)
  • Gary C. Evans, Independent Director (Age 59)
  • Michael A. McManus Jr., J.D., Independent Director (Age 74)

Who owns Novavax stock?

Novavax's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.39%), Chicago Equity Partners LLC (0.36%), Canada Pension Plan Investment Board (0.19%), Wells Fargo & Company MN (0.14%), Brown Advisory Inc. (0.05%) and Nationwide Fund Advisors (0.05%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Who sold Novavax stock? Who is selling Novavax stock?

Novavax's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors and Chicago Equity Partners LLC. View Insider Buying and Selling for Novavax.

Who bought Novavax stock? Who is buying Novavax stock?

Novavax's stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Canada Pension Plan Investment Board, Schwab Charles Investment Management Inc. and Brown Advisory Inc.. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of Novavax stock can currently be purchased for approximately $1.29.

How big of a company is Novavax?

Novavax has a market capitalization of $361.85 million and generates $15.35 million in revenue each year. The biopharmaceutical company earns ($279,960,000.00) in net income (profit) each year or ($0.68) on an earnings per share basis. Novavax employs 355 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 20 Firstfield Rd, GAITHERSBURG, MD 20878-1760, United States. The biopharmaceutical company can be reached via phone at +1-240-2682000 or via email at ir@novavax.com.


MarketBeat Community Rating for Novavax (NASDAQ NVAX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  427
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Novavax (NASDAQ:NVAX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $3.43 (166.15% upside)

Consensus Price Target History for Novavax (NASDAQ:NVAX)

Price Target History for Novavax (NASDAQ:NVAX)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Cantor FitzgeraldReiterated RatingHold$2.00N/AView Rating Details
10/31/2017Citigroup Inc.UpgradeNeutral -> Buy$2.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingNeutralN/AView Rating Details
8/9/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$1.60HighView Rating Details
7/27/2017Chardan CapitalReiterated RatingNeutral$1.50LowView Rating Details
7/26/2017Piper Jaffray CompaniesReiterated RatingHold$1.50LowView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Novavax (NASDAQ:NVAX)

Earnings by Quarter for Novavax (NASDAQ:NVAX)

Earnings History by Quarter for Novavax (NASDAQ NVAX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.16)($0.15)$6.42 million$8.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.16)($0.16)$6.15 million$6.70 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novavax (NASDAQ:NVAX)
2017 EPS Consensus Estimate: ($0.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.19)($0.17)($0.18)
Q2 20172($0.16)($0.16)($0.16)
Q3 20172($0.17)($0.16)($0.17)
Q4 20173($0.16)($0.14)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Novavax (NASDAQ NVAX)

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 38.87%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Insider Trades by Quarter for Novavax (NASDAQ NVAX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2017Stanley C ErckInsiderBuy100,000$1.13$113,000.00View SEC Filing  
8/31/2017James F. YoungDirectorSell175,000$1.06$185,500.00View SEC Filing  
7/31/2017Barclay A. PhillipsCFOBuy2,057$0.89$1,830.73View SEC Filing  
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.00View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novavax (NASDAQ NVAX)

Source:
DateHeadline
3 Reasons Novavax Stock Could Double in 20183 Reasons Novavax Stock Could Double in 2018
www.fool.com - November 18 at 8:55 AM
Novavax, Inc. (NVAX) Lowered to Sell at Zacks Investment ResearchNovavax, Inc. (NVAX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 16 at 6:32 AM
Novavax, Inc. (NVAX) Jumps: Stock Rises 8.4% - Yahoo Finance - Yahoo FinanceNovavax, Inc. (NVAX) Jumps: Stock Rises 8.4% - Yahoo Finance - Yahoo Finance
finance.yahoo.com - November 15 at 6:58 AM
Today’s Research Reports on Trending Tickers: Novavax and Sarepta TherapeuticsToday’s Research Reports on Trending Tickers: Novavax and Sarepta Therapeutics
finance.yahoo.com - November 15 at 6:58 AM
Novavax, Inc. (NVAX) Jumps: Stock Rises 8.4%Novavax, Inc. (NVAX) Jumps: Stock Rises 8.4%
finance.yahoo.com - November 15 at 6:58 AM
Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 14, 2017Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 14, 2017
finance.yahoo.com - November 15 at 6:58 AM
Novavax Inc (NVAX) President and CEO Stanley C Erck Bought $113,000 of SharesNovavax Inc (NVAX) President and CEO Stanley C Erck Bought $113,000 of Shares
www.nasdaq.com - November 14 at 6:16 AM
Novavax, Inc. (NVAX) Insider Acquires $113,000.00 in StockNovavax, Inc. (NVAX) Insider Acquires $113,000.00 in Stock
www.americanbankingnews.com - November 13 at 3:12 PM
FY2017 EPS Estimates for Novavax, Inc. Raised by Analyst (NVAX)FY2017 EPS Estimates for Novavax, Inc. Raised by Analyst (NVAX)
www.americanbankingnews.com - November 13 at 2:36 AM
ETFs with exposure to Novavax, Inc. : November 10, 2017ETFs with exposure to Novavax, Inc. : November 10, 2017
finance.yahoo.com - November 12 at 11:09 AM
Novavax, Inc. (NVAX) Short Interest UpdateNovavax, Inc. (NVAX) Short Interest Update
www.americanbankingnews.com - November 12 at 1:32 AM
Novavax, Inc. (NVAX) Forecasted to Earn FY2018 Earnings of ($0.59) Per ShareNovavax, Inc. (NVAX) Forecasted to Earn FY2018 Earnings of ($0.59) Per Share
www.americanbankingnews.com - November 10 at 5:38 PM
Heres Why the Best Is Yet to Come for Novavax, Inc.Here's Why the Best Is Yet to Come for Novavax, Inc.
www.fool.com - November 9 at 10:36 AM
Novavax in position to seek flu vaccine approval in 2019 - Washington Business JournalNovavax in position to seek flu vaccine approval in 2019 - Washington Business Journal
www.bizjournals.com - November 9 at 7:49 AM
Novavax Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Novavax Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 7:49 AM
The case for Novavax - Motley FoolThe case for Novavax - Motley Fool
www.fool.com - November 9 at 7:49 AM
Novavax to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)Novavax to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 9 at 7:49 AM
Edited Transcript of NVAX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of NVAX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 7:49 AM
G1 builds out executive team as it eyes important results in 2018G1 builds out executive team as it eyes important results in 2018
finance.yahoo.com - November 9 at 7:49 AM
Novavax in position to seek flu vaccine approval in 2019Novavax in position to seek flu vaccine approval in 2019
finance.yahoo.com - November 9 at 7:49 AM
Novavax to Present at the Stifel 2017 Healthcare ConferenceNovavax to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 9 at 7:49 AM
Novavax, Inc. (NVAX) Given "Hold" Rating at Cantor FitzgeraldNovavax, Inc. (NVAX) Given "Hold" Rating at Cantor Fitzgerald
www.americanbankingnews.com - November 8 at 11:40 PM
EARNINGS SUMMARY: Details of Novavax Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Novavax Inc. Q3 Earnings Report
www.rttnews.com - November 7 at 9:31 PM
Novavax reports 3Q lossNovavax reports 3Q loss
finance.yahoo.com - November 7 at 9:31 PM
Novavax, Inc. (NVAX) Issues  Earnings Results, Beats Expectations By $0.01 EPSNovavax, Inc. (NVAX) Issues Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 7 at 6:35 PM
Novavax Reports Third Quarter 2017 Financial ResultsNovavax Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 4:27 PM
Novavax, Inc. – Value Analysis (NASDAQ:NVAX) : November 6, 2017Novavax, Inc. – Value Analysis (NASDAQ:NVAX) : November 6, 2017
finance.yahoo.com - November 7 at 7:55 AM
Better Buy: Novavax, Inc. vs. Pfizer Inc.Better Buy: Novavax, Inc. vs. Pfizer Inc.
finance.yahoo.com - November 7 at 7:55 AM
Novavax, Inc. (NVAX) Receives Consensus Rating of "Hold" from BrokeragesNovavax, Inc. (NVAX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 5:38 PM
Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 3, 2017Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 3, 2017
finance.yahoo.com - November 4 at 8:15 AM
Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - November 1 at 7:04 AM
-$0.16 Earnings Per Share Expected for Novavax, Inc. (NVAX) This Quarter-$0.16 Earnings Per Share Expected for Novavax, Inc. (NVAX) This Quarter
www.americanbankingnews.com - October 31 at 5:22 PM
Why Novavax Stock Is Soaring TodayWhy Novavax Stock Is Soaring Today
www.fool.com - October 31 at 3:14 PM
Novavax Stock Upgraded: 3 Things You Need to KnowNovavax Stock Upgraded: 3 Things You Need to Know
www.fool.com - October 31 at 1:35 PM
Novavax The Downtrodden Finally Finds A New Bull At CitiNovavax The Downtrodden Finally Finds A New Bull At Citi
feeds.benzinga.com - October 31 at 11:15 AM
Comparing Novavax (NVAX) and Seattle Genetics (SGEN)Comparing Novavax (NVAX) and Seattle Genetics (SGEN)
www.americanbankingnews.com - October 20 at 2:10 PM
Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017
finance.yahoo.com - October 19 at 7:00 AM
Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017
finance.yahoo.com - October 19 at 7:00 AM
Novavax: Down A CFO But Not Out - Seeking AlphaNovavax: Down A CFO But Not Out - Seeking Alpha
seekingalpha.com - October 18 at 7:50 AM
Featured Company News - Novavaxs CFO ResignsFeatured Company News - Novavax's CFO Resigns
finance.yahoo.com - October 17 at 3:21 AM
Novavax CFO Phillips resigns to pursue other opportunity in the industryNovavax CFO Phillips resigns to pursue other opportunity in the industry
finance.yahoo.com - October 14 at 6:18 AM
Novavax announces a major leadership changeNovavax announces a major leadership change
finance.yahoo.com - October 14 at 6:18 AM
Novavax Announces Leadership ChangeNovavax Announces Leadership Change
finance.yahoo.com - October 13 at 7:34 AM
Todays Research Reports on Trending Tickers: AVEO Pharmaceuticals and NovavaxToday's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Novavax
finance.yahoo.com - October 9 at 3:57 PM
Equities Analysts Set Expectations for Novavax, Inc.s FY2017 Earnings (NVAX)Equities Analysts Set Expectations for Novavax, Inc.'s FY2017 Earnings (NVAX)
www.americanbankingnews.com - October 9 at 3:16 AM
Novavaxs (NVAX) Neutral Rating Reaffirmed at Seaport Global SecuritiesNovavax's (NVAX) Neutral Rating Reaffirmed at Seaport Global Securities
www.americanbankingnews.com - October 7 at 2:58 PM
Novavax: Beware Of The Siren Song - Seeking AlphaNovavax: Beware Of The Siren Song - Seeking Alpha
seekingalpha.com - October 5 at 12:48 PM
How Should You Think About Novavax Inc’s (NVAX) Risks?How Should You Think About Novavax Inc’s (NVAX) Risks?
finance.yahoo.com - September 30 at 5:40 PM
Contrasting Novavax (NVAX) & Its PeersContrasting Novavax (NVAX) & Its Peers
www.americanbankingnews.com - September 29 at 6:24 PM
Why Novavax, Inc. Could Be a Gold Mine for Growth Investors - Motley FoolWhy Novavax, Inc. Could Be a Gold Mine for Growth Investors - Motley Fool
www.fool.com - September 24 at 6:26 AM

Social Media

Financials

Chart

Novavax (NASDAQ NVAX) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.